Efficacy and Safety of Prophylactic Antibiotics in Preventing Ventilator-associated Pneumonia: A Randomized, Double Blind, Placebo-controlled Trial
NCT ID: NCT07203638
Last Updated: 2025-10-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ENROLLING_BY_INVITATION
NA
100 participants
INTERVENTIONAL
2024-11-01
2025-11-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Management of Ventilation Acquired Pneumonia Caused by Pseudomonas and Acinetobacter Organisms in a Pediatric Center
NCT06739382
Nebulized Ceftazidime and Amikacin in Ventilator Associated Pneumonia
NCT00786305
Antibiotic Prophylaxis for Early Ventilator-associated Pneumonia in Neurological Patients
NCT01118403
Effect of Aerosolised Colistin in Ventilator Associated Pneumonia
NCT02683603
Adjunctive Therapy to Antibiotics in the Treatment of S. Aureus Ventilator-Associated Pneumonia With AR-301
NCT03816956
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
B.lactam
Patient recieved beta lactam iv 1gm each 12h for 2 days
Beta Lactam Antibiotics
Beta lactam cefipim infusion (20mg/kg -12h -2 days ) total volume 10 ml
Control group
patients in the control group will receive saline iv each 12h for 2 days
Salin
Patient will receive .9 % saline (10ml /12h/2days)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Beta Lactam Antibiotics
Beta lactam cefipim infusion (20mg/kg -12h -2 days ) total volume 10 ml
Salin
Patient will receive .9 % saline (10ml /12h/2days)
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Both sexes will be included.
* Invasive mechanical ventilation
Exclusion Criteria
* previous lung disease precluding accurate interpretation of chest radiographs
* ongoing antibiotic therapy or during the week before admission
* known chronic colonization with multidrug-resistant bacteria
* known allergy to beta-lactam antibiotics
* Pregnancy
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Esraa Salah Mohamed Abdallah Eladl
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Esraa Salah Mohamed Abdallah Eladl
Assistant Lecturer of Critical Care Medicine
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Benha university hospital
Banhā, Al-Qalyubia, Egypt
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MD 1-11-2024
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.